Spectrum & Viropro to develop rituximab biosimilar
Spectrum Pharmaceuticals and Viropro are to develop a biosimilar version of rituximab, a monoclonal antibody cancer treatment sold by Roche and Biogen Idec.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs